Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Apr 8, 2020-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹-- FreeStyle Libre 14 day system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan² to minimize exposure to COVID-19 and preserve use of personal protective equipment (PPE)-- In partnership with the American Diabetes Association (ADA), Abbott will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology
Mar 27, 2020- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
Feb 20, 2020- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology
Feb 19, 2020- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control- Jan 30, 2020- First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option- Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients- Together with MitraClip™, Tendyne expands Abbott's market-leading portfolio of innovative minimally invasive mitral valve solutions
- Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe